4-氧代-4-(苯乙氧基)丁酸 | 153824-41-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 4-氧代-4-(苯乙氧基)丁酸
• 中文别名: 4-氧-4-(苯乙氧基)丁酸
• 英文名称: succinic acid monophenethyl ester
• 英文别名: 4-oxo-4-phenethoxybutanoic acid；4-Oxo-4-(phenethyloxy)butanoic acid；4-oxo-4-(2-phenylethoxy)butanoic acid
• CAS: 153824-41-0
• 化学式: C₁₂H₁₄O₄
• mdl: MFCD05870554
• 分子量: 222.241
• InChiKey: IRVZRNOWHCEDRV-UHFFFAOYSA-N

物化性质

• 沸点：
  392.0±25.0 °C(Predicted)
• 密度：
  1.192±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  4-氧代-4-(苯乙氧基)丁酸 在 氯化亚砜 作用下， 生成 3-chlorocarbonyl-propionic acid phenethyl ester
  参考文献：
  名称：

  Precursor compounds

  摘要：

  公式I的化合物是感官和抗菌化合物的前体。后者在皮肤细菌、酶或酸性或碱性条件下生成。一个前体分子可以提供一个或多个不同的化合物。

  公开号：

  US06207857B1
• 作为产物：
  描述：

  2-phenylethyl 2-(trimethylsilyl)ethyl succinate 在 四丁基氟化铵 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 以80%的产率得到4-氧代-4-(苯乙氧基)丁酸
  参考文献：
  名称：

  Kita, Yasuyuki; Maeda, Hiroshi; Takahashi, Fumie, Journal of the Chemical Society. Perkin transactions I, 1993, # 21, p. 2639 - 2650

  摘要：

  DOI：

文献信息

• Zn(ClO4)2·6H2O as a Powerful Catalyst for a Practical Acylation of Alcohols with Acid Anhydrides
  作者：Giuseppe Bartoli、Marcella Bosco、Renato Dalpozzo、Enrico Marcantoni、Massimo Massaccesi、Letizia Sambri

  DOI：10.1002/ejoc.200300458

  日期：2003.12

  new protocol for the acylation of alcohols with anhydrides in the presence of Zn(ClO4)2·6H2O as the catalyst is reported. The activity of Zn(ClO4)2·6H2O has been proven to be superior to that exerted by dry Mg(ClO4)2 and by metal triflates. Its efficiency allows reactions between poorly reactive substrates, such as sterically hindered tertiary alcohols and aromatic anhydrides. All of the reactions

  报道了一种在 Zn(ClO4)2·6H2O 作为催化剂的情况下用酸酐酰化醇的新方案。已证明 Zn(ClO4)2·6H2O 的活性优于干燥的 Mg(ClO4)2 和金属三氟甲磺酸盐。其效率允许反应性较差的底物（例如位阻叔醇和芳香酸酐）之间发生反应。所有反应均以1:1.05的醇/酸酐比进行。从实用和经济的角度来看，这些条件非常方便，因为它们避免了试剂的浪费并允许简单的后处理程序。Zn(ClO4)2·6H2O 的催化作用对酸酐的活化非常特殊，以至于在酯化过程中对酸敏感的官能团和起始材料的立体化学构型保持不变。在所有情况下，酰化产物都是以纯形式定量获得的。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003)
• [EN] CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS<br/>[FR] COMPOSES D'ACIDE CARBAMIQUE COMPRENANT UNE LIAISON ESTER OU CETONE, UTILISES COMME INHIBITEURS DE L'HISTONE DESACETYLASE
  申请人：TOPOTARGET UK LTD

  公开号：WO2004065354A1

  公开（公告）日：2004-08-05

  This invention pertains to certain carbamic acid compounds of the formula (I), which inhibit HDAC (histone deacetylase) activity: wherein: J is a linking functional group and is independently: -O-C(=O)- or -C(=O)-O- or - C(=O)-; Cy is a cyclyl group and is independently: C3-20carbocyclyl, C3-20heterocyclyl, or C5-20aryl; and is optionally substituted; Q1 is a cyclyl leader group, and is independently a divalent bidentate group obtained by removing two hydrogen atoms from a ring carbon atom of a saturated monocyclic hydrocarbon having from 4 to 7 ring atoms, or by removing two hydrogen atoms from a ring carbon atom of saturated monocyclic heterocyclic compound having from 4 to 7 ring atoms including 1 nitrogen ring atom or 1 oxygen ring atom; and is optionally substituted; Q2 is an acid leader group, and is independently: C1-8alkylene; and is optionally substituted; or: Q2 is an acid leader group, and is independently: C5-20arylene; C5-20arylene-C1-7alkylene; C1-7alkylene-C5-20arylene; or C1-7alkylene-C5-20arylene-C1-7alkylene; and is optionally substituted; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC,and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

  这项发明涉及某些具有以下式(I)的氨甲酸化合物，其抑制HDAC（组蛋白去乙酰化酶）活性：其中：J是一个连接的功能基团，独立地为：-O-C(=O)-或-C(=O)-O-或-C(=O)-；Cy是一个环烷基团，独立地为：C3-20碳环烷基、C3-20杂环烷基或C5-20芳基；并且可以选择性地被取代；Q1是一个环烷基领头基团，独立地是通过从具有4至7个环原子的饱和单环碳氢化合物的环碳原子中去除两个氢原子获得的双价双齿基团，或者通过从具有4至7个环原子，包括1个氮环原子或1个氧环原子的饱和单环杂环化合物的环碳原子中去除两个氢原子获得的双价双齿基团；并且可以选择性地被取代；Q2是一个酸领头基团，独立地为：C1-8烷基烯；并且可以选择性地被取代；或者：Q2是一个酸领头基团，独立地为：C5-20芳基烯；C5-20芳基烯-C1-7烷基烯；C1-7烷基烯-C5-20芳基烯；或C1-7烷基烯-C5-20芳基烯-C1-7烷基烯；并且可以选择性地被取代；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包括这种化合物的药物组合物，以及在体内外使用这种化合物和组合物来抑制HDAC，并用于治疗由HDAC介导的疾病、癌症、增殖性疾病、牛皮癣等。
• Oxidative Decarboxylation Enables Chemoselective, Racemization-Free Esterification: Coupling of α-Ketoacids and Alcohols Mediated by Hypervalent Iodine(III)
  作者：Takeshi Nanjo、Natsuki Kato、Yoshiji Takemoto

  DOI：10.1021/acs.orglett.8b02466

  日期：2018.9.21

  α-ketoacid could be converted into a reactive acylating agent by treatment with hypervalent iodine(III) species, and in so doing, we discovered a novel decarboxylative acylation of alcohols that affords a variety of esters in excellent yields. The esterification has been applied to a sterol bearing a free carboxylic acid and shows unique chemoselectivity. The procedure is racemization-free and operates

  通过用高价碘（III）处理可以将α-酮酸转化为反应性酰化剂，这样做，我们发现了一种新型的醇脱羧酰化反应，该酯以优异的收率提供了各种酯。酯化反应已应用于带有游离羧酸的甾醇，并显示出独特的化学选择性。该程序无消旋，且在温和条件下运行。
• Cooling Compounds
  申请人：Furrer Stefan Michael

  公开号：US20080311232A1

  公开（公告）日：2008-12-18

  A cooling composition comprising at least one compound of the Formula I in which R is selected from the group of moieties consisting of (CH 2 ) n COOR″; (CH 2 ) n CONMe 2 ; (CH 2 ) n OR″; and CHNH 2 CH 3 ; where n is 1-3 and R″ is independently selected from hydrogen, methyl and ethyl; and R′ is selected from the group consisting of the moieties fenchyl, D-bornyl, L-bornyl, exo-norbornyl, 2-methylisobornyl, 2-ethylfenchyl, 2-methylbornyl, cis-pinan-2-yl, verbanyl and isobornyl. The compositions are useful in providing cooling sensations to the skin or mucous membranes of the body.

  一种冷却组合物，包括至少一种符合以下式I的化合物，其中R选自(CH2)nCOOR″；(CH2)nCONMe2；(CH2)nOR″；和CHNH2CH3的基团组成的群；其中n为1-3，R″独立地选自氢、甲基和乙基；R′选自蕴含蕴含蕴含蕴含的基团，蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴含蕴
• Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors
  申请人：Finn W Paul

  公开号：US20060058282A1

  公开（公告）日：2006-03-16

  This invention pertains to certain carbamic acid compounds of the formula (I), which inhibit HDAC (histone deacetylase) activity: wherein: J is a linking functional group and is independently: —O—C(═O)— or —C(═O)—O— or —C(═O)—; Cy is a cyclyl group and is independently: C 3-20 carbocyclyl, C 3-20 heterocyclyl, or C 5-20 aryl; and is optionally substituted; Q 1 is a cyclyl leader group, and is independently a divalent bidentate group obtained by removing two hydrogen atoms from a ring carbon atom of a saturated monocyclic hydrocarbon having from 4 to 7 ring atoms, or by removing two hydrogen atoms from a ring carbon atom of saturated monocyclic heterocyclic compound having from 4 to 7 ring atoms including 1 nitrogen ring atom or 1 oxygen ring atom; and is optionally substituted; Q 2 is an acid leader group, and is independently: C 1-8 alkylene; and is optionally substituted; or: Q 2 is an acid leader group, and is independently: C 5-20 arylene; C 5-20 arylene-C 1-7 alkylene; C 1-7 alkylene-C 5-20 arylene; or C 1-7 alkylene-C 5-20 arylene-C 1-7 alkylene; and is optionally substituted; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

  该发明涉及一类具有以下式子(I)的碳酰胺化合物，其抑制HDAC（组蛋白去乙酰化酶）活性：其中：J是连接功能基团，独立地为：—O—C(═O)—或—C(═O)—O—或—C(═O)—；Cy是环基团，独立地为：C3-20碳环基、C3-20杂环基或C5-20芳基；并且可以选择性地被取代；Q1是环基领导基团，独立地为从具有4至7个环原子的饱和单环烃或包括1个氮环原子或1个氧环原子的饱和单环杂环化合物的环碳原子上去除两个氢原子而得到的二价双齿基团；并且可以选择性地被取代；Q2是酸基领导基团，独立地为：C1-8烷基；并且可以选择性地被取代；或：Q2是酸基领导基团，独立地为：C5-20芳基、C5-20芳基-C1-7烷基、C1-7烷基-C5-20芳基或C1-7烷基-C5-20芳基-C1-7烷基；并且可以选择性地被取代；以及其药学上可接受的盐、溶剂化物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这样的化合物的制药组合物，以及这样的化合物和组合物的使用，无论是在体外还是体内，用于抑制HDAC，以及用于治疗由HDAC介导的疾病，如癌症、增生性疾病、牛皮癣等。